Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

The Use of the Montreal Cognitive Assessment to Predict Neurotoxicity Post CD19 and BCMA CART

Hannah Katz, Lauren N Scott, Pilar Thangwaritorn, Jianzheng Wu, William Wesson, Dinesh Pal Mudaranthakam, Shaun DeJarnette, Al-Ola Abdallah, Marc Hoffmann, Forat Lutfi, Sunil Abhyankar, Leyla O. Shune, Muhammad Umair Mushtaq, Anurag Singh, Haitham Abdelhakim, Joseph P. McGuirk, Muhammad Mahdi Nashatizadeh, Liz Muenks, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 5030.

https://doi.org/10.1182/blood-2024-199312

Published: 2024

Journal Articles

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) for Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and T-Cell Engager Antibody (TCE) in Myeloma and Lymphoma

Fathima Shehnaz Ayoobkhan, Raabia Qureshi, Raeef L Rahman, Zohaa Faiz, Sohaib Irfan, Ahmad Iftikhar, Briha Ansari, Muhammad Umair Mushtaq, Al-Ola Abdallah, Shahzad Raza, Hira Shaikh, Forat Lutfi, Shebli Atrash, Joseph P. McGuirk, Hamza Hashmi, Faiz Anwer, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 5163.

https://doi.org/10.1182/blood-2024-208307

Published: 2024

Journal Articles

Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry

Blood (2024) 144 (Supplement 1): 5092.

https://doi.org/10.1182/blood-2024-198455

Published: 2024

Journal Articles

Avascular Necrosis (AVN) Outcomes in Allogeneic Stem Cell Transplant Recipients

Blood (2024) 144 (Supplement 1): 7414.

https://doi.org/10.1182/blood-2024-206235

Published: 2024

Journal Articles

Sociodemographic Determinants of Allogeneic Hematopoietic Stem Cell Transplant Outcomes

Matthew McGuirk, Moazzam Shahzad, Sohaib Irfan, Muhammad Kashif Amin, Sibgha Gull Chaudhary, Iqra Anwar, Shaun DeJarnette, Forat Lutfi, Al-Ola Abdallah, Anurag K. Singh, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 7410.

https://doi.org/10.1182/blood-2024-193655

Published: 2024

Journal Articles

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Blood (2024) 144 (Supplement 1): 6451.

https://doi.org/10.1182/blood-2024-194844

Published: 2024

Journal Articles

Utilization of Investigations for Neurotoxicity in CD19 and BCMA CART Recipients

Lauren N Scott, William Wesson, Pilar Thangwaritorn, Raeef L Rahman, Forat Lutfi, Marc Hoffmann, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Al-Ola Abdallah, Sunil Abhyankar, Joseph P. McGuirk, Muhammad Mahdi Nashatizadeh, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 389.

https://doi.org/10.1182/blood-2024-205983

Published: 2024

Journal Articles

Outcomes of Outpatient CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory B-Cell Lymphomas: A Systematic Review and Meta-Analysis

Moazzam Shahzad, Jawad Noor, Muhammad Kashif Amin, Zubia Zaman, Umar Akram, Maryyam Sharif, Hameer Ali, Uzma Qayyum, Muhammad Waqas Khan, Sheena Shamoon, Bidushi Pokhrel, Asim Ahmad Khan, Hira Habib, Sibgha Gull Chaudhary, Iqra Anwar, Forat Lutfi, Leyla O. Shune, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 6502.

https://doi.org/10.1182/blood-2024-202760

Published: 2024

Journal Articles

Global Trends of Burden of Chronic Myeloid Leukemia Based on Socio-Demographic Index (SDI): A Comparative Epidemiological Study

Prashant Chaulagain, Ashmita Poudel, Saurav Aryal, Chiranjeevi Sainatham, Forat Lutfi

Blood (2024) 144 (Supplement 1): 7918.

https://doi.org/10.1182/blood-2024-210443

Published: 2024

Journal Articles

Incidence and Severity of Cytopenias Secondary to CD19-Targeted CAR-T Cell Therapy: A Systemic Review and Meta-Analysis

Blood (2024) 144 (Supplement 1): 7242.

https://doi.org/10.1182/blood-2024-206536

Published: 2024

Journal Articles

Impact of Absolute Lymphocyte Count on Efficacy and Toxicity of T-Cell Engagers in Non-Hodgkin's Lymphoma

Jordan Snyder, Nausheen Ahmed, Aqeeb Ur Rehman, Muhammad Umair Mushtaq, Aung M. Tun, Al-Ola Abdallah, Marc Hoffmann, Forat Lutfi

Blood (2024) 144 (Supplement 1): 7731.

https://doi.org/10.1182/blood-2024-207753

Published: 2024

Journal Articles

Absolute Lymphocyte Count As a Predictor of Safety and Efficacy Post CART for Multiple Myeloma and B Cell Malignancies

Raeef L Rahman, Jianzheng Wu, Lauren N Scott, William Wesson, Razan Mansour, Aung M. Tun, Marc Hoffmann, Al-Ola Abdallah, Dinesh Pal Mudaranthakam, Joseph P. McGuirk, Nausheen Ahmed, Forat Lutfi

Blood (2024) 144 (Supplement 1): 7099.

https://doi.org/10.1182/blood-2024-205978

Published: 2024

Journal Articles

The Scope of Academic and Industry Sponsorship in Shaping the Future of AL Amyloidosis Research

Anas Zayad, Nausheen Ahmed, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Evguenia Ouchveridze, Forat Lutfi, Joseph P. McGuirk, Al-Ola Abdallah, Faiz Anwer, Manisha Bhutani, Shebli Atrash

Blood (2024) 144 (Supplement 1): 7595.

https://doi.org/10.1182/blood-2024-205422

Published: 2024

Journal Articles

Characterizing Treatment Patterns in Multiple Myeloma Patients with High-Risk Cytogenetics: A 15-Year-Study

Priyanka Venkatesh, Raeef L Rahman, Aroog Khaliq, Mehak M Laharwal, Shebli Atrash, Joseph P. McGuirk, Forat Lutfi, Muhammad Umair Mushtaq, Al-Ola Abdallah, Nausheen Ahmed, Prerna Mewawalla, Jordan Snyder, Zahra Mahmoudjafari

Blood (2024) 144 (Supplement 1): 6943.

https://doi.org/10.1182/blood-2024-211572

Published: 2024

Journal Articles

Stalled CARS. Examining the Real-World Impact of Waiting for CART in Patients with Multiple Myeloma

Michael Weise, Muhammad Umair Mushtaq, Shebli Atrash, Al-Ola Abdallah, Joseph P. McGuirk, Forat Lutfi, Barry Skikne, Nausheen Ahmed, Zahra Mahmoudjafari

Blood (2024) 144 (Supplement 1): 6937.

https://doi.org/10.1182/blood-2024-208299

Published: 2024

Journal Articles

Real World Experience with a Zuma -1 Cohort 4 Adopted Approach to CRS and Icans in CAR-T Recipients

Chiranjeevi Sainatham, Olga Goloubeva, Philip Margiotta, Hanan Alharthy, Imari Patel, Ali Bukhari, Jennie Law, Seung Tae Lee, Mehmet H. Kocoglu, Jean A. Yared, Nancy M. Hardy, Maggie Nelson, Joseph P McGuirk, Aaron P. Rapoport, Saurabh Dahiya, Forat Lutfi

Blood (2023) 142 (Supplement 1): 2122.

https://doi.org/10.1182/blood-2023-183002

Published: 2023

Journal Articles

Comparison of Biosimilar Filgrastim (Nivestym) Versus Originator Filgrastim (Neupogen) for Peripheral Blood Stem Cell Mobilization for Allogeneic Hematopoietic Stem Cell Transplantation

Moazzam Shahzad, Joe S. Al-Ramahi, Muhammad Kashif Amin, Muhammad Fareed Khalid, Shaun DeJarnette, Zahra Mahmoudjafari, Maggie Nelson, Riley Hastings, Haitham Abdelhakim, Forat Lutfi, Nausheen Ahmed, Rajat Bansal, Leyla Shune, Al-Ola Abdallah, Anurag K. Singh, Sunil Abhyankar, Joseph P McGuirk, Muhammad Umair Mushtaq

Blood (2023) 142 (Supplement 1): 3523.

https://doi.org/10.1182/blood-2023-185652

Published: 2023

Journal Articles

Trends in Access to Cellular Therapies in Multiple Myeloma (TACTUM): Perspectives of Treating Versus Referring Physicians

Rawan Atallah, Md Saiful Islam Saif, Danai Dima, Anuj Shrestha, Faiz Anwer, Muhammad Umair Mushtaq, Forat Lutfi, Leyla Shune, Hamza Hashmi, Siddhartha Ganguly, Joseph P McGuirk, Shebli Atrash, Al-Ola Abdallah, Rahul Banerjee, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 6678.

https://doi.org/10.1182/blood-2023-181218

Published: 2023

Journal Articles

Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL)

Saurabh Dahiya, Jay Y. Spiegel, Dasom Lee, Turab Mohammed, Forat Lutfi, Anmol Goyal, Caroline Hana, Julio C Chavez, Filip Ionescu, Matthew J. Frank, Sushma Bharadwaj, Jose Sandoval-Sus, Amer M. Beitinjaneh, Lazaros J. Lekakis, Joseph P McGuirk, Frederick L. Locke, David B. Miklos, Michael D. Jain

Blood (2023) 142 (Supplement 1): 4876.

https://doi.org/10.1182/blood-2023-188918

Published: 2023

Journal Articles

Outcomes after Bone Marrow Versus Peripheral Blood Stem Cell Matched Unrelated Donor Hematopoietic Stem Cell Transplantation

Joe S. Al-Ramahi, Moazzam Shahzad, Muhammad Kashif Amin, Shaun DeJarnette, Maggie Nelson, Forat Lutfi, Nausheen Ahmed, Haitham Abdelhakim, Rajat Bansal, Leyla Shune, Al-Ola Abdallah, Anurag K. Singh, Sunil Abhyankar, Joseph P McGuirk, Muhammad Umair Mushtaq

Blood (2023) 142 (Supplement 1): 7028.

https://doi.org/10.1182/blood-2023-185209

Published: 2023

NARROW

The Use of the Montreal Cognitive Assessment to Predict Neurotoxicity Post CD19 and BCMA CART

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) for Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and T-Cell Engager Antibody (TCE) in Myeloma and Lymphoma

Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry

Avascular Necrosis (AVN) Outcomes in Allogeneic Stem Cell Transplant Recipients

Sociodemographic Determinants of Allogeneic Hematopoietic Stem Cell Transplant Outcomes

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Utilization of Investigations for Neurotoxicity in CD19 and BCMA CART Recipients

Outcomes of Outpatient CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory B-Cell Lymphomas: A Systematic Review and Meta-Analysis

Global Trends of Burden of Chronic Myeloid Leukemia Based on Socio-Demographic Index (SDI): A Comparative Epidemiological Study

Incidence and Severity of Cytopenias Secondary to CD19-Targeted CAR-T Cell Therapy: A Systemic Review and Meta-Analysis

Impact of Absolute Lymphocyte Count on Efficacy and Toxicity of T-Cell Engagers in Non-Hodgkin's Lymphoma

Absolute Lymphocyte Count As a Predictor of Safety and Efficacy Post CART for Multiple Myeloma and B Cell Malignancies

The Scope of Academic and Industry Sponsorship in Shaping the Future of AL Amyloidosis Research

Characterizing Treatment Patterns in Multiple Myeloma Patients with High-Risk Cytogenetics: A 15-Year-Study

Stalled CARS. Examining the Real-World Impact of Waiting for CART in Patients with Multiple Myeloma

Real World Experience with a Zuma -1 Cohort 4 Adopted Approach to CRS and Icans in CAR-T Recipients

Comparison of Biosimilar Filgrastim (Nivestym) Versus Originator Filgrastim (Neupogen) for Peripheral Blood Stem Cell Mobilization for Allogeneic Hematopoietic Stem Cell Transplantation

Trends in Access to Cellular Therapies in Multiple Myeloma (TACTUM): Perspectives of Treating Versus Referring Physicians

Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL)

Outcomes after Bone Marrow Versus Peripheral Blood Stem Cell Matched Unrelated Donor Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only